Microbiome Drugs Industry Research Report 2023
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
Highlights
The global Microbiome Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.
The Microbiome Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Microbiome Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Microbiome Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Microbiome Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Microbiome Drugs segment by Type
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Microbiome Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Microbiome Drugs market.
Microbiome Drugs Segment by Symptom
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Microbiome Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Microbiome Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Highlights
The global Microbiome Drugs market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.
The Microbiome Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Microbiome Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Microbiome Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- Rebiotix
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Osel
Global markets are presented by Microbiome Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Microbiome Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Microbiome Drugs segment by Type
- Oral Dosage Form
- Enteric Capsules
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Microbiome Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Microbiome Drugs market.
Microbiome Drugs Segment by Symptom
- Gastrointestinal Disorders
- Autoimmune Disorders
- Diabetes
- Cancer
- Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Microbiome Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Microbiome Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Microbiome Drugs by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
2.3 Microbiome Drugs by Symptom
2.3.1 Market Value Comparison by Symptom (2018 VS 2022 VS 2029)
2.3.2 Gastrointestinal Disorders
2.3.3 Autoimmune Disorders
2.3.4 Diabetes
2.3.5 Cancer
2.3.6 Others
2.4 Assumptions and Limitations
3 MICROBIOME DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Microbiome Drugs Historic Market Size by Type (2018-2023)
3.2 Global Microbiome Drugs Forecasted Market Size by Type (2023-2028)
4 MICROBIOME DRUGS BREAKDOWN DATA BY SYMPTOM
4.1 Global Microbiome Drugs Historic Market Size by Symptom (2018-2023)
4.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Microbiome Drugs Market Perspective (2018-2029)
5.2 Global Microbiome Drugs Growth Trends by Region
5.2.1 Global Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Microbiome Drugs Historic Market Size by Region (2018-2023)
5.2.3 Microbiome Drugs Forecasted Market Size by Region (2024-2029)
5.3 Microbiome Drugs Market Dynamics
5.3.1 Microbiome Drugs Industry Trends
5.3.2 Microbiome Drugs Market Drivers
5.3.3 Microbiome Drugs Market Challenges
5.3.4 Microbiome Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Microbiome Drugs Players by Revenue
6.1.1 Global Top Microbiome Drugs Players by Revenue (2018-2023)
6.1.2 Global Microbiome Drugs Revenue Market Share by Players (2018-2023)
6.2 Global Microbiome Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Microbiome Drugs Head office and Area Served
6.4 Global Microbiome Drugs Players, Product Type & Application
6.5 Global Microbiome Drugs Players, Date of Enter into This Industry
6.6 Global Microbiome Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Microbiome Drugs Market Size (2018-2029)
7.2 North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Microbiome Drugs Market Size by Country (2018-2023)
7.4 North America Microbiome Drugs Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Microbiome Drugs Market Size (2018-2029)
8.2 Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Microbiome Drugs Market Size by Country (2018-2023)
8.4 Europe Microbiome Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Microbiome Drugs Market Size (2018-2029)
9.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023)
9.4 Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Microbiome Drugs Market Size (2018-2029)
10.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Microbiome Drugs Market Size by Country (2018-2023)
10.4 Latin America Microbiome Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Microbiome Drugs Market Size (2018-2029)
11.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023)
11.4 Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Detail
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Drugs Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022)
11.1.5 Seres Therapeutics Recent Development
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Detail
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Drugs Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022)
11.2.5 Assembly Biosciences Recent Development
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Detail
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Drugs Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022)
11.3.5 Synthetic Biologics Recent Development
11.4 Interxon
11.4.1 Interxon Company Detail
11.4.2 Interxon Business Overview
11.4.3 Interxon Microbiome Drugs Introduction
11.4.4 Interxon Revenue in Microbiome Drugs Business (2017-2022)
11.4.5 Interxon Recent Development
11.5 PureTech
11.5.1 PureTech Company Detail
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Drugs Introduction
11.5.4 PureTech Revenue in Microbiome Drugs Business (2017-2022)
11.5.5 PureTech Recent Development
11.6 Synlogic
11.6.1 Synlogic Company Detail
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Drugs Introduction
11.6.4 Synlogic Revenue in Microbiome Drugs Business (2017-2022)
11.6.5 Synlogic Recent Development
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Detail
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Drugs Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022)
11.7.5 Enterome BioScience Recent Development
11.8 4D Pharma
11.8.1 4D Pharma Company Detail
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Drugs Introduction
11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2017-2022)
11.8.5 4D Pharma Recent Development
11.9 Second Genome
11.9.1 Second Genome Company Detail
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Drugs Introduction
11.9.4 Second Genome Revenue in Microbiome Drugs Business (2017-2022)
11.9.5 Second Genome Recent Development
11.10 AOBiome
11.10.1 AOBiome Company Detail
11.10.2 AOBiome Business Overview
11.10.3 AOBiome Microbiome Drugs Introduction
11.10.4 AOBiome Revenue in Microbiome Drugs Business (2017-2022)
11.10.5 AOBiome Recent Development
11.11 Rebiotix
11.11.1 Rebiotix Company Detail
11.11.2 Rebiotix Business Overview
11.11.3 Rebiotix Microbiome Drugs Introduction
11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2017-2022)
11.11.5 Rebiotix Recent Development
11.12 Metabiomics
11.12.1 Metabiomics Company Detail
11.12.2 Metabiomics Business Overview
11.12.3 Metabiomics Microbiome Drugs Introduction
11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2017-2022)
11.12.5 Metabiomics Recent Development
11.13 Ritter Pharmaceuticals
11.13.1 Ritter Pharmaceuticals Company Detail
11.13.2 Ritter Pharmaceuticals Business Overview
11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction
11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022)
11.13.5 Ritter Pharmaceuticals Recent Development
11.14 Symberix
11.14.1 Symberix Company Detail
11.14.2 Symberix Business Overview
11.14.3 Symberix Microbiome Drugs Introduction
11.14.4 Symberix Revenue in Microbiome Drugs Business (2017-2022)
11.14.5 Symberix Recent Development
11.15 OpenBiome
11.15.1 OpenBiome Company Detail
11.15.2 OpenBiome Business Overview
11.15.3 OpenBiome Microbiome Drugs Introduction
11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2017-2022)
11.15.5 OpenBiome Recent Development
11.16 Azitra
11.16.1 Azitra Company Detail
11.16.2 Azitra Business Overview
11.16.3 Azitra Microbiome Drugs Introduction
11.16.4 Azitra Revenue in Microbiome Drugs Business (2017-2022)
11.16.5 Azitra Recent Development
11.17 Osel
11.17.1 Osel Company Detail
11.17.2 Osel Business Overview
11.17.3 Osel Microbiome Drugs Introduction
11.17.4 Osel Revenue in Microbiome Drugs Business (2017-2022)
11.17.5 Osel Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Microbiome Drugs by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
2.3 Microbiome Drugs by Symptom
2.3.1 Market Value Comparison by Symptom (2018 VS 2022 VS 2029)
2.3.2 Gastrointestinal Disorders
2.3.3 Autoimmune Disorders
2.3.4 Diabetes
2.3.5 Cancer
2.3.6 Others
2.4 Assumptions and Limitations
3 MICROBIOME DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Microbiome Drugs Historic Market Size by Type (2018-2023)
3.2 Global Microbiome Drugs Forecasted Market Size by Type (2023-2028)
4 MICROBIOME DRUGS BREAKDOWN DATA BY SYMPTOM
4.1 Global Microbiome Drugs Historic Market Size by Symptom (2018-2023)
4.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Microbiome Drugs Market Perspective (2018-2029)
5.2 Global Microbiome Drugs Growth Trends by Region
5.2.1 Global Microbiome Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Microbiome Drugs Historic Market Size by Region (2018-2023)
5.2.3 Microbiome Drugs Forecasted Market Size by Region (2024-2029)
5.3 Microbiome Drugs Market Dynamics
5.3.1 Microbiome Drugs Industry Trends
5.3.2 Microbiome Drugs Market Drivers
5.3.3 Microbiome Drugs Market Challenges
5.3.4 Microbiome Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Microbiome Drugs Players by Revenue
6.1.1 Global Top Microbiome Drugs Players by Revenue (2018-2023)
6.1.2 Global Microbiome Drugs Revenue Market Share by Players (2018-2023)
6.2 Global Microbiome Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Microbiome Drugs Head office and Area Served
6.4 Global Microbiome Drugs Players, Product Type & Application
6.5 Global Microbiome Drugs Players, Date of Enter into This Industry
6.6 Global Microbiome Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Microbiome Drugs Market Size (2018-2029)
7.2 North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Microbiome Drugs Market Size by Country (2018-2023)
7.4 North America Microbiome Drugs Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Microbiome Drugs Market Size (2018-2029)
8.2 Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Microbiome Drugs Market Size by Country (2018-2023)
8.4 Europe Microbiome Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Microbiome Drugs Market Size (2018-2029)
9.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023)
9.4 Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Microbiome Drugs Market Size (2018-2029)
10.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Microbiome Drugs Market Size by Country (2018-2023)
10.4 Latin America Microbiome Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Microbiome Drugs Market Size (2018-2029)
11.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023)
11.4 Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Detail
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Drugs Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022)
11.1.5 Seres Therapeutics Recent Development
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Detail
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Drugs Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022)
11.2.5 Assembly Biosciences Recent Development
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Detail
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Drugs Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022)
11.3.5 Synthetic Biologics Recent Development
11.4 Interxon
11.4.1 Interxon Company Detail
11.4.2 Interxon Business Overview
11.4.3 Interxon Microbiome Drugs Introduction
11.4.4 Interxon Revenue in Microbiome Drugs Business (2017-2022)
11.4.5 Interxon Recent Development
11.5 PureTech
11.5.1 PureTech Company Detail
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Drugs Introduction
11.5.4 PureTech Revenue in Microbiome Drugs Business (2017-2022)
11.5.5 PureTech Recent Development
11.6 Synlogic
11.6.1 Synlogic Company Detail
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Drugs Introduction
11.6.4 Synlogic Revenue in Microbiome Drugs Business (2017-2022)
11.6.5 Synlogic Recent Development
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Detail
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Drugs Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022)
11.7.5 Enterome BioScience Recent Development
11.8 4D Pharma
11.8.1 4D Pharma Company Detail
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Drugs Introduction
11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2017-2022)
11.8.5 4D Pharma Recent Development
11.9 Second Genome
11.9.1 Second Genome Company Detail
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Drugs Introduction
11.9.4 Second Genome Revenue in Microbiome Drugs Business (2017-2022)
11.9.5 Second Genome Recent Development
11.10 AOBiome
11.10.1 AOBiome Company Detail
11.10.2 AOBiome Business Overview
11.10.3 AOBiome Microbiome Drugs Introduction
11.10.4 AOBiome Revenue in Microbiome Drugs Business (2017-2022)
11.10.5 AOBiome Recent Development
11.11 Rebiotix
11.11.1 Rebiotix Company Detail
11.11.2 Rebiotix Business Overview
11.11.3 Rebiotix Microbiome Drugs Introduction
11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2017-2022)
11.11.5 Rebiotix Recent Development
11.12 Metabiomics
11.12.1 Metabiomics Company Detail
11.12.2 Metabiomics Business Overview
11.12.3 Metabiomics Microbiome Drugs Introduction
11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2017-2022)
11.12.5 Metabiomics Recent Development
11.13 Ritter Pharmaceuticals
11.13.1 Ritter Pharmaceuticals Company Detail
11.13.2 Ritter Pharmaceuticals Business Overview
11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction
11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022)
11.13.5 Ritter Pharmaceuticals Recent Development
11.14 Symberix
11.14.1 Symberix Company Detail
11.14.2 Symberix Business Overview
11.14.3 Symberix Microbiome Drugs Introduction
11.14.4 Symberix Revenue in Microbiome Drugs Business (2017-2022)
11.14.5 Symberix Recent Development
11.15 OpenBiome
11.15.1 OpenBiome Company Detail
11.15.2 OpenBiome Business Overview
11.15.3 OpenBiome Microbiome Drugs Introduction
11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2017-2022)
11.15.5 OpenBiome Recent Development
11.16 Azitra
11.16.1 Azitra Company Detail
11.16.2 Azitra Business Overview
11.16.3 Azitra Microbiome Drugs Introduction
11.16.4 Azitra Revenue in Microbiome Drugs Business (2017-2022)
11.16.5 Azitra Recent Development
11.17 Osel
11.17.1 Osel Company Detail
11.17.2 Osel Business Overview
11.17.3 Osel Microbiome Drugs Introduction
11.17.4 Osel Revenue in Microbiome Drugs Business (2017-2022)
11.17.5 Osel Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Symptom (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Microbiome Drugs Revenue Market Share by Type (2018-2023)
Table 7. Global Microbiome Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Microbiome Drugs Revenue Market Share by Type (2024-2029)
Table 9. Global Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 10. Global Microbiome Drugs Revenue Market Share by Symptom (2018-2023)
Table 11. Global Microbiome Drugs Forecasted Market Size by Symptom (2024-2029) & (US$ Million)
Table 12. Global Microbiome Drugs Revenue Market Share by Symptom (2024-2029)
Table 13. Global Microbiome Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Microbiome Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Microbiome Drugs Market Share by Region (2018-2023)
Table 16. Global Microbiome Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Microbiome Drugs Market Share by Region (2024-2029)
Table 18. Microbiome Drugs Market Trends
Table 19. Microbiome Drugs Market Drivers
Table 20. Microbiome Drugs Market Challenges
Table 21. Microbiome Drugs Market Restraints
Table 22. Global Top Microbiome Drugs Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Microbiome Drugs Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Microbiome Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Microbiome Drugs, Headquarters and Area Served
Table 26. Global Microbiome Drugs Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Microbiome Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Seres Therapeutics Company Detail
Table 46. Seres Therapeutics Business Overview
Table 47. Seres Therapeutics Microbiome Drugs Product
Table 48. Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 49. Seres Therapeutics Recent Development
Table 50. Assembly Biosciences Company Detail
Table 51. Assembly Biosciences Business Overview
Table 52. Assembly Biosciences Microbiome Drugs Product
Table 53. Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 54. Assembly Biosciences Recent Development
Table 55. Synthetic Biologics Company Detail
Table 56. Synthetic Biologics Business Overview
Table 57. Synthetic Biologics Microbiome Drugs Product
Table 58. Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 59. Synthetic Biologics Recent Development
Table 60. Interxon Company Detail
Table 61. Interxon Business Overview
Table 62. Interxon Microbiome Drugs Product
Table 63. Interxon Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 64. Interxon Recent Development
Table 65. PureTech Company Detail
Table 66. PureTech Business Overview
Table 67. PureTech Microbiome Drugs Product
Table 68. PureTech Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 69. PureTech Recent Development
Table 70. Synlogic Company Detail
Table 71. Synlogic Business Overview
Table 72. Synlogic Microbiome Drugs Product
Table 73. Synlogic Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 74. Synlogic Recent Development
Table 75. Enterome BioScience Company Detail
Table 76. Enterome BioScience Business Overview
Table 77. Enterome BioScience Microbiome Drugs Product
Table 78. Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 79. Enterome BioScience Recent Development
Table 80. 4D Pharma Company Detail
Table 81. 4D Pharma Business Overview
Table 82. 4D Pharma Microbiome Drugs Product
Table 83. 4D Pharma Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 84. 4D Pharma Recent Development
Table 85. Second Genome Company Detail
Table 86. Second Genome Business Overview
Table 87. Second Genome Microbiome Drugs Product
Table 88. Second Genome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 89. Second Genome Recent Development
Table 90. AOBiome Company Detail
Table 91. AOBiome Business Overview
Table 92. AOBiome Microbiome Drugs Product
Table 93. AOBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 94. AOBiome Recent Development
Table 95. Rebiotix Company Detail
Table 96. Rebiotix Business Overview
Table 97. Rebiotix Microbiome DrugsProduct
Table 98. Rebiotix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 99. Rebiotix Recent Development
Table 100. Metabiomics Company Detail
Table 101. Metabiomics Business Overview
Table 102. Metabiomics Microbiome DrugsProduct
Table 103. Metabiomics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 104. Metabiomics Recent Development
Table 105. Ritter Pharmaceuticals Company Detail
Table 106. Ritter Pharmaceuticals Business Overview
Table 107. Ritter Pharmaceuticals Microbiome DrugsProduct
Table 108. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 109. Ritter Pharmaceuticals Recent Development
Table 110. Symberix Company Detail
Table 111. Symberix Business Overview
Table 112. Symberix Microbiome DrugsProduct
Table 113. Symberix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 114. Symberix Recent Development
Table 115. OpenBiome Company Detail
Table 116. OpenBiome Business Overview
Table 117. OpenBiome Microbiome DrugsProduct
Table 118. OpenBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 119. OpenBiome Recent Development
Table 120. Azitra Company Detail
Table 121. Azitra Business Overview
Table 122. Azitra Microbiome DrugsProduct
Table 123. Azitra Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 124. Azitra Recent Development
Table 125. Osel Company Detail
Table 126. Osel Business Overview
Table 127. Osel Microbiome DrugsProduct
Table 128. Osel Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 129. Osel Recent Development
Table 130. Seres Therapeutics Company Information
Table 131. Seres Therapeutics Business Overview
Table 132. Seres Therapeutics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 133. Seres Therapeutics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 134. Seres Therapeutics Recent Development
Table 135. Assembly Biosciences Company Information
Table 136. Assembly Biosciences Business Overview
Table 137. Assembly Biosciences Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 138. Assembly Biosciences Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 139. Assembly Biosciences Recent Development
Table 140. Synthetic Biologics Company Information
Table 141. Synthetic Biologics Business Overview
Table 142. Synthetic Biologics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 143. Synthetic Biologics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 144. Synthetic Biologics Recent Development
Table 145. Interxon Company Information
Table 146. Interxon Business Overview
Table 147. Interxon Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 148. Interxon Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 149. Interxon Recent Development
Table 150. PureTech Company Information
Table 151. PureTech Business Overview
Table 152. PureTech Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 153. PureTech Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 154. PureTech Recent Development
Table 155. Synlogic Company Information
Table 156. Synlogic Business Overview
Table 157. Synlogic Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 158. Synlogic Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 159. Synlogic Recent Development
Table 160. Enterome BioScience Company Information
Table 161. Enterome BioScience Business Overview
Table 162. Enterome BioScience Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 163. Enterome BioScience Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 164. Enterome BioScience Recent Development
Table 165. 4D Pharma Company Information
Table 166. 4D Pharma Business Overview
Table 167. 4D Pharma Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 168. 4D Pharma Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 169. 4D Pharma Recent Development
Table 170. Second Genome Company Information
Table 171. Second Genome Business Overview
Table 172. Second Genome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 173. Second Genome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 174. Second Genome Recent Development
Table 175. AOBiome Company Information
Table 176. AOBiome Business Overview
Table 177. AOBiome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 178. AOBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 179. AOBiome Recent Development
Table 180. Rebiotix Company Information
Table 181. Rebiotix Business Overview
Table 182. Rebiotix Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 183. Rebiotix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 184. Rebiotix Recent Development
Table 185. Metabiomics Company Information
Table 186. Metabiomics Business Overview
Table 187. Metabiomics Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 188. Metabiomics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 189. Metabiomics Recent Development
Table 190. Ritter Pharmaceuticals Company Information
Table 191. Ritter Pharmaceuticals Business Overview
Table 192. Ritter Pharmaceuticals Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 193. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 194. Ritter Pharmaceuticals Recent Development
Table 195. Symberix Company Information
Table 196. Symberix Business Overview
Table 197. Symberix Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 198. Symberix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 199. Symberix Recent Development
Table 200. OpenBiome Company Information
Table 201. OpenBiome Business Overview
Table 202. OpenBiome Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 203. OpenBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 204. OpenBiome Recent Development
Table 205. Azitra Company Information
Table 206. Azitra Business Overview
Table 207. Azitra Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 208. Azitra Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 209. Azitra Recent Development
Table 210. Osel Company Information
Table 211. Osel Business Overview
Table 212. Osel Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 213. Osel Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 214. Osel Recent Development
Table 215. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Symptom (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Microbiome Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Microbiome Drugs Revenue Market Share by Type (2018-2023)
Table 7. Global Microbiome Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Microbiome Drugs Revenue Market Share by Type (2024-2029)
Table 9. Global Microbiome Drugs Market Size by Symptom (2018-2023) & (US$ Million)
Table 10. Global Microbiome Drugs Revenue Market Share by Symptom (2018-2023)
Table 11. Global Microbiome Drugs Forecasted Market Size by Symptom (2024-2029) & (US$ Million)
Table 12. Global Microbiome Drugs Revenue Market Share by Symptom (2024-2029)
Table 13. Global Microbiome Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Microbiome Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Microbiome Drugs Market Share by Region (2018-2023)
Table 16. Global Microbiome Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Microbiome Drugs Market Share by Region (2024-2029)
Table 18. Microbiome Drugs Market Trends
Table 19. Microbiome Drugs Market Drivers
Table 20. Microbiome Drugs Market Challenges
Table 21. Microbiome Drugs Market Restraints
Table 22. Global Top Microbiome Drugs Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Microbiome Drugs Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Microbiome Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Microbiome Drugs, Headquarters and Area Served
Table 26. Global Microbiome Drugs Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Microbiome Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Microbiome Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Seres Therapeutics Company Detail
Table 46. Seres Therapeutics Business Overview
Table 47. Seres Therapeutics Microbiome Drugs Product
Table 48. Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 49. Seres Therapeutics Recent Development
Table 50. Assembly Biosciences Company Detail
Table 51. Assembly Biosciences Business Overview
Table 52. Assembly Biosciences Microbiome Drugs Product
Table 53. Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 54. Assembly Biosciences Recent Development
Table 55. Synthetic Biologics Company Detail
Table 56. Synthetic Biologics Business Overview
Table 57. Synthetic Biologics Microbiome Drugs Product
Table 58. Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 59. Synthetic Biologics Recent Development
Table 60. Interxon Company Detail
Table 61. Interxon Business Overview
Table 62. Interxon Microbiome Drugs Product
Table 63. Interxon Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 64. Interxon Recent Development
Table 65. PureTech Company Detail
Table 66. PureTech Business Overview
Table 67. PureTech Microbiome Drugs Product
Table 68. PureTech Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 69. PureTech Recent Development
Table 70. Synlogic Company Detail
Table 71. Synlogic Business Overview
Table 72. Synlogic Microbiome Drugs Product
Table 73. Synlogic Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 74. Synlogic Recent Development
Table 75. Enterome BioScience Company Detail
Table 76. Enterome BioScience Business Overview
Table 77. Enterome BioScience Microbiome Drugs Product
Table 78. Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 79. Enterome BioScience Recent Development
Table 80. 4D Pharma Company Detail
Table 81. 4D Pharma Business Overview
Table 82. 4D Pharma Microbiome Drugs Product
Table 83. 4D Pharma Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 84. 4D Pharma Recent Development
Table 85. Second Genome Company Detail
Table 86. Second Genome Business Overview
Table 87. Second Genome Microbiome Drugs Product
Table 88. Second Genome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 89. Second Genome Recent Development
Table 90. AOBiome Company Detail
Table 91. AOBiome Business Overview
Table 92. AOBiome Microbiome Drugs Product
Table 93. AOBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 94. AOBiome Recent Development
Table 95. Rebiotix Company Detail
Table 96. Rebiotix Business Overview
Table 97. Rebiotix Microbiome DrugsProduct
Table 98. Rebiotix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 99. Rebiotix Recent Development
Table 100. Metabiomics Company Detail
Table 101. Metabiomics Business Overview
Table 102. Metabiomics Microbiome DrugsProduct
Table 103. Metabiomics Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 104. Metabiomics Recent Development
Table 105. Ritter Pharmaceuticals Company Detail
Table 106. Ritter Pharmaceuticals Business Overview
Table 107. Ritter Pharmaceuticals Microbiome DrugsProduct
Table 108. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 109. Ritter Pharmaceuticals Recent Development
Table 110. Symberix Company Detail
Table 111. Symberix Business Overview
Table 112. Symberix Microbiome DrugsProduct
Table 113. Symberix Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 114. Symberix Recent Development
Table 115. OpenBiome Company Detail
Table 116. OpenBiome Business Overview
Table 117. OpenBiome Microbiome DrugsProduct
Table 118. OpenBiome Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 119. OpenBiome Recent Development
Table 120. Azitra Company Detail
Table 121. Azitra Business Overview
Table 122. Azitra Microbiome DrugsProduct
Table 123. Azitra Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 124. Azitra Recent Development
Table 125. Osel Company Detail
Table 126. Osel Business Overview
Table 127. Osel Microbiome DrugsProduct
Table 128. Osel Revenue in Microbiome Drugs Business (2017-2022) & (US$ Million)
Table 129. Osel Recent Development
Table 130. Seres Therapeutics Company Information
Table 131. Seres Therapeutics Business Overview
Table 132. Seres Therapeutics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 133. Seres Therapeutics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 134. Seres Therapeutics Recent Development
Table 135. Assembly Biosciences Company Information
Table 136. Assembly Biosciences Business Overview
Table 137. Assembly Biosciences Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 138. Assembly Biosciences Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 139. Assembly Biosciences Recent Development
Table 140. Synthetic Biologics Company Information
Table 141. Synthetic Biologics Business Overview
Table 142. Synthetic Biologics Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 143. Synthetic Biologics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 144. Synthetic Biologics Recent Development
Table 145. Interxon Company Information
Table 146. Interxon Business Overview
Table 147. Interxon Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 148. Interxon Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 149. Interxon Recent Development
Table 150. PureTech Company Information
Table 151. PureTech Business Overview
Table 152. PureTech Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 153. PureTech Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 154. PureTech Recent Development
Table 155. Synlogic Company Information
Table 156. Synlogic Business Overview
Table 157. Synlogic Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 158. Synlogic Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 159. Synlogic Recent Development
Table 160. Enterome BioScience Company Information
Table 161. Enterome BioScience Business Overview
Table 162. Enterome BioScience Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 163. Enterome BioScience Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 164. Enterome BioScience Recent Development
Table 165. 4D Pharma Company Information
Table 166. 4D Pharma Business Overview
Table 167. 4D Pharma Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 168. 4D Pharma Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 169. 4D Pharma Recent Development
Table 170. Second Genome Company Information
Table 171. Second Genome Business Overview
Table 172. Second Genome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 173. Second Genome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 174. Second Genome Recent Development
Table 175. AOBiome Company Information
Table 176. AOBiome Business Overview
Table 177. AOBiome Microbiome Drugs Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 178. AOBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 179. AOBiome Recent Development
Table 180. Rebiotix Company Information
Table 181. Rebiotix Business Overview
Table 182. Rebiotix Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 183. Rebiotix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 184. Rebiotix Recent Development
Table 185. Metabiomics Company Information
Table 186. Metabiomics Business Overview
Table 187. Metabiomics Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 188. Metabiomics Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 189. Metabiomics Recent Development
Table 190. Ritter Pharmaceuticals Company Information
Table 191. Ritter Pharmaceuticals Business Overview
Table 192. Ritter Pharmaceuticals Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 193. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 194. Ritter Pharmaceuticals Recent Development
Table 195. Symberix Company Information
Table 196. Symberix Business Overview
Table 197. Symberix Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 198. Symberix Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 199. Symberix Recent Development
Table 200. OpenBiome Company Information
Table 201. OpenBiome Business Overview
Table 202. OpenBiome Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 203. OpenBiome Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 204. OpenBiome Recent Development
Table 205. Azitra Company Information
Table 206. Azitra Business Overview
Table 207. Azitra Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 208. Azitra Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 209. Azitra Recent Development
Table 210. Osel Company Information
Table 211. Osel Business Overview
Table 212. Osel Microbiome DrugsRevenue in Microbiome Drugs Business (2018-2023) & (US$ Million)
Table 213. Osel Revenue in Microbiome Drugs Business (2018-2023) & (US$ Million) Portfolio
Table 214. Osel Recent Development
Table 215. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Microbiome Drugs Product Picture
Figure 5. Global Microbiome Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Microbiome Drugs Market Share by Type: 2022 VS 2029
Figure 7. Oral Dosage Form Product Picture
Figure 8. Enteric Capsules Product Picture
Figure 9. Global Microbiome Drugs Market Size by Symptom (2023-2029) & (US$ Million)
Figure 10. Global Microbiome Drugs Market Share by Symptom: 2022 VS 2029
Figure 11. Gastrointestinal Disorders Product Picture
Figure 12. Autoimmune Disorders Product Picture
Figure 13. Diabetes Product Picture
Figure 14. Cancer Product Picture
Figure 15. Others Product Picture
Figure 16. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Microbiome Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Microbiome Drugs Market Share by Region: 2022 VS 2029
Figure 19. Global Microbiome Drugs Market Share by Players in 2022
Figure 20. Global Microbiome Drugs Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Microbiome Drugs Market Share by Country (2018-2029)
Figure 25. United States Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Microbiome Drugs Market Share by Country (2018-2029)
Figure 29. Germany Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Microbiome Drugs Market Share by Country (2018-2029)
Figure 37. China Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Microbiome Drugs Market Share by Country (2018-2029)
Figure 45. Mexico Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Microbiome Drugs Market Share by Country (2018-2029)
Figure 49. Turkey Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 53. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 54. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 55. Interxon Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 56. PureTech Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 57. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 58. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 59. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 60. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 61. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 62. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 63. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 64. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 65. Symberix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 66. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 67. Azitra Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 68. Osel Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Microbiome Drugs Product Picture
Figure 5. Global Microbiome Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Microbiome Drugs Market Share by Type: 2022 VS 2029
Figure 7. Oral Dosage Form Product Picture
Figure 8. Enteric Capsules Product Picture
Figure 9. Global Microbiome Drugs Market Size by Symptom (2023-2029) & (US$ Million)
Figure 10. Global Microbiome Drugs Market Share by Symptom: 2022 VS 2029
Figure 11. Gastrointestinal Disorders Product Picture
Figure 12. Autoimmune Disorders Product Picture
Figure 13. Diabetes Product Picture
Figure 14. Cancer Product Picture
Figure 15. Others Product Picture
Figure 16. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Microbiome Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Microbiome Drugs Market Share by Region: 2022 VS 2029
Figure 19. Global Microbiome Drugs Market Share by Players in 2022
Figure 20. Global Microbiome Drugs Players, Date of Enter into This Industry
Figure 21. Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2022
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 23. North America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Microbiome Drugs Market Share by Country (2018-2029)
Figure 25. United States Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Canada Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe Microbiome Drugs Market Share by Country (2018-2029)
Figure 29. Germany Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Asia-Pacific Microbiome Drugs Market Share by Country (2018-2029)
Figure 37. China Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Japan Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. South Korea Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Southeast Asia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. India Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Australia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Latin America Microbiome Drugs Market Share by Country (2018-2029)
Figure 45. Mexico Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Brazil Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Microbiome Drugs Market Share by Country (2018-2029)
Figure 49. Turkey Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. UAE Microbiome Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 53. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 54. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 55. Interxon Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 56. PureTech Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 57. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 58. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 59. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 60. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 61. AOBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 62. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 63. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 64. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 65. Symberix Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 66. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 67. Azitra Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
Figure 68. Osel Revenue Growth Rate in Microbiome Drugs Business (2018-2023)
